Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Autor: Tarantino P; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Tayob N; Harvard Medical School, Boston, MA.; Division of Data Science, Dana-Farber Cancer Institute, Boston, MA., Villacampa G; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Oncology Data Science Vall d'Hebron Institute of Oncology, Barcelona, Spain., Dang C; Memorial Sloan Kettering Cancer Center, New York, NY., Yardley DA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN., Isakoff SJ; Harvard Medical School, Boston, MA.; Massachusetts General Hospital, Boston, MA., Valero V; MD Anderson Cancer Center, Houston, TX., Faggen M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Mulvey T; Harvard Medical School, Boston, MA.; Massachusetts General Hospital, Boston, MA., Bose R; Washington University School of Medicine, St Louis, MO., Weckstein D; New Hampshire Oncology Hematology, Manchester, NH., Wolff AC; Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC., Reeder-Hayes K; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Rugo HS; University of California, San Francisco, CA., Ramaswamy B; Ohio State University Comprehensive Cancer Center, Columbus, OH., Zuckerman D; St Luke's Mountain States Tumor Institute, Boise, ID., Hart L; Wake Forest Baptist Health, Winston-Salem, NC., Gadi VK; University of Illinois Cancer Center, Chicago, IL., Constantine M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Cheng K; North Shore-LIJ Cancer Institute, Lake Success, NY., Garrett AM; Northern Light Cancer Care, Brewer, ME., Marcom PK; Duke University School of Medicine, Durham, NC., Albain K; Loyola University Medical Center, Maywood, IL., DeFusco P; Hartford Healthcare Cancer Institute, Hartford, CT., Tung N; Harvard Medical School, Boston, MA.; Beth Israel Deaconess Medical Center, Boston, MA., Ardman B; Lowell General Hospital, Lowell, MA., Nanda R; UChicago Medicine, Chicago, IL., Jankowitz RC; Perelman Center for Advanced Medicine, Philadelphia, PA., Rimawi M; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Abramson V; Vanderbilt-Ingram Cancer Center, Nashville, TN., Pohlmann PR; MD Anderson Cancer Center, Houston, TX.; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC., Van Poznak C; Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Forero-Torres A; Kirklin UAB Hematology Oncology, Birmingham, AL., Liu MC; Natera, Inc, Austin, TX., Ruddy KJ; Mayo Clinic, Rochester, NY., Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., DeMeo M; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA., Burstein HJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Dell'Orto P; IEO European Institute of Oncology, IRCCS, Milan, Italy., Russo L; IEO European Institute of Oncology, IRCCS, Milan, Italy., Krause E; PathAI, Boston, MA., Newhouse DJ; NanoString Technologies, Inc, Boston, MA., Kurt BB; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA., Schneider B; Indiana University School of Medicine, Indianapolis, IN., Prat A; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain., Winer EP; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Yale Cancer Center, New Haven, CT., Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Yale Cancer Center, New Haven, CT., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Nov; Vol. 42 (31), pp. 3652-3665. Date of Electronic Publication: 2024 Jun 27.

International survey on invasive lobular breast cancer identifies priority research questions.

Autor: Oesterreich S; University of Pittsburgh, Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, Women's Cancer Research Center, Magee Womens Research Institute, Pittsburgh, PA, USA. oesterreichs@upmc.edu., Pate L; Independent ILC Advocate, Founder LBCA, Pittsburgh, PA, USA., Lee AV; University of Pittsburgh, Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, Women's Cancer Research Center, Magee Womens Research Institute, Pittsburgh, PA, USA.; Institute for Precision Medicine, University of Pittsburgh and UPMC, Pittsburgh, PA, USA., Chen F; University of Pittsburgh, Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, Women's Cancer Research Center, Magee Womens Research Institute, Pittsburgh, PA, USA.; Tsinghua University, Beijing, China., Jankowitz RC; University of Pennsylvania and Penn Medicine Abramson Cancer Center, Philadelphia, PA, USA., Mukhtar R; University of California, San Francisco, Department of Surgery, San Francisco, CA, USA., Metzger O; Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA., Sikora MJ; Dept. of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Li CI; Fred Hutchinson Cancer Center, Division of Public Health Sciences, Seattle, WA, USA., Sotiriou C; Jules Bordet Institute Belgium, Brussels, Belgium., Shah OS; University of Pittsburgh, Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, Women's Cancer Research Center, Magee Womens Research Institute, Pittsburgh, PA, USA., Koorman T; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Ulaner G; Molecular Imaging and Therapy, Hoag Family Cancer Institute, Molecular Imaging and Therapy, Irvine, CA. Departments of Radiology and Translational Genomics, University of Southern California, Los Angeles, CA, USA., Reis-Filho JS; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; AstraZeneca, GAITHERSBURG, MARYLAND, USA., Davidson NM; Fred Hutchinson Cancer Center, Division of Public Health Sciences, Seattle, WA, USA., Van Baelen K; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium., Hutcheson L; Lobular Breast Cancer Alliance Inc., White Horse Beach, MA, USA., Freeney S; Lobular Ireland, Dublin, Ireland., Migyanka F; Dynami Foundation, Wausau, WI, USA., Turner C; Lobular Breast Cancer UK, Nottingham, UK., Derksen P; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Bear T; Department of Family Medicine, University of Pittsburgh, Pittsburgh, patients/advocates, Pittsburgh, PA, USA., Desmedt C; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.

Publikováno v: NPJ breast cancer [NPJ Breast Cancer] 2024 Jul 20; Vol. 10 (1), pp. 61. Date of Electronic Publication: 2024 Jul 20.

Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.

Autor: Jacobs SA; NSABP Foundation, Pittsburgh, PA, USA. jacobssa1945@gmail.com., Wang Y; NSABP Foundation, Pittsburgh, PA, USA., Abraham J; NSABP Foundation, Pittsburgh, PA, USA.; Cleveland Clinic, Taussig Cancer Institute, Weston, Cleveland, OH, USA., Feng H; NSABP Foundation, Pittsburgh, PA, USA., Montero AJ; NSABP Foundation, Pittsburgh, PA, USA.; Cleveland Clinic, Taussig Cancer Institute, Weston, Cleveland, OH, USA.; University Hospitals/Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA., Lipchik C; NSABP Foundation, Pittsburgh, PA, USA., Finnigan M; NSABP Foundation, Pittsburgh, PA, USA., Jankowitz RC; NSABP Foundation, Pittsburgh, PA, USA.; University of Pittsburgh, Pittsburgh, PA, USA.; University of Pennsylvania Perelman School of Medicine, State College, Philadelphia, PA, USA., Salkeni MA; NSABP Foundation, Pittsburgh, PA, USA.; National Institutes of Health, Washington, DC, USA.; Virginia Cancer Specialists, Fairfax, VA, USA., Maley SK; NSABP Foundation, Pittsburgh, PA, USA., Puhalla SL; NSABP Foundation, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Piette F; International Drug Development Institute, Louvain-la-Neuve, Belgium., Quinn K; Guardant Health, Redwood City, CA, USA., Chang K; Guardant Health, Redwood City, CA, USA., Nagy RJ; Guardant Health, Redwood City, CA, USA., Allegra CJ; NSABP Foundation, Pittsburgh, PA, USA.; University of Florida Health, Gainesville, FL, USA., Vehec K; NSABP Foundation, Pittsburgh, PA, USA., Wolmark N; NSABP Foundation, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Lucas PC; NSABP Foundation, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Srinivasan A; NSABP Foundation, Pittsburgh, PA, USA.; Autism Impact Fund, Pittsburgh, PA, USA., Pogue-Geile KL; NSABP Foundation, Pittsburgh, PA, USA.

Publikováno v: Breast cancer research : BCR [Breast Cancer Res] 2024 May 24; Vol. 26 (1), pp. 83. Date of Electronic Publication: 2024 May 24.

Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study.

Autor: Sanft TB; 1Yale School of Medicine, New Haven, CT., Wong J; 2Biotheranostics, A Hologic Company, San Diego, CA., O'Neal B; 2Biotheranostics, A Hologic Company, San Diego, CA., Siuliukina N; 2Biotheranostics, A Hologic Company, San Diego, CA., Jankowitz RC; 3University of Pennsylvania, Philadelphia, PA., Pegram MD; 4Stanford Comprehensive Cancer Institute, Palo Alto, CA., Fox JR; 5Rocky Mountain Cancer Center, US Oncology, Boulder, CO., Zhang Y; 2Biotheranostics, A Hologic Company, San Diego, CA., Treuner K; 2Biotheranostics, A Hologic Company, San Diego, CA., O'Shaughnessy JA; 6Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX.

Publikováno v: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2024 Mar 04; Vol. 22 (2), pp. 99-107. Date of Electronic Publication: 2024 Mar 04.

Temporal Trends and Factors Associated with Receipt of Post-mastectomy Radiation After Neoadjuvant Chemotherapy in Women with cT3 Breast Cancer.

Autor: Manik R; Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.; Harvard Medical School, Boston, MA, USA., Grady CB; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA., Elmore LC; Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA., Fieber JH; Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.; Division of Surgical Oncology, Department of Surgery, University of Florida, Gainesville, FL, USA., Freedman GM; Rena Rowan Breast Center, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA, USA.; Department of Radiation Oncology, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA., Jankowitz RC; Rena Rowan Breast Center, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA., Tchou JC; Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.; Rena Rowan Breast Center, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA, USA.; Leonard Davis Institute of Health Economics (LDI), The University of Pennsylvania, Philadelphia, PA, USA., Zhang JQ; Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.; Rena Rowan Breast Center, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA, USA., Hubbard RA; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA., Fayanju OM; Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA. Oluwadamilola.Fayanju@pennmedicine.upenn.edu.; Rena Rowan Breast Center, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA, USA. Oluwadamilola.Fayanju@pennmedicine.upenn.edu.; Leonard Davis Institute of Health Economics (LDI), The University of Pennsylvania, Philadelphia, PA, USA. Oluwadamilola.Fayanju@pennmedicine.upenn.edu.; Penn Center for Cancer Care Innovation (PC3I), Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA, USA. Oluwadamilola.Fayanju@pennmedicine.upenn.edu.

Publikováno v: Annals of surgical oncology [Ann Surg Oncol] 2023 Oct; Vol. 30 (11), pp. 6506-6515. Date of Electronic Publication: 2023 Jul 17.